89Zr-N-sucDf-pembrolizumab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug Name89Zr-N-sucDf-pembrolizumab
Drug Alias Name89Zr-TFP-N-sucDf-Pembrolizumab[89Zr]N-sucDf-pembrolizumab
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedDiagnostic agent (In vivo) > Radionuclide Imaging agent
Mechanisms of ActionAnti-PD-1
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck & Co IncUmcg The University Medical Center Groningen
China Registration ClassN/A

Develop Information

Active CompaniesMerck & Co IncUmcg The University Medical Center Groningen
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A